Retatrutide
LY3437943, triple GIP/GLP-1/glucagon receptor agonist
A single-molecule triple agonist at the GIP, GLP-1 and glucagon receptors — the most-discussed metabolic research peptide of the current cycle.
Scan the QR code on your vial, or type the batch number, and you get the analytical data for the exact vial you received.
Verify your vial →Mitochondrial ORF of the 12S rRNA type-c
A 16-amino-acid peptide encoded in mitochondrial DNA rather than the nuclear genome — a mitochondrial-derived peptide studied as an exercise mimetic.
MOTS-c is translated from a short open reading frame within the mitochondrial 12S rRNA gene, making it one of a small class of mitochondrially encoded hormones. Published work reports that it targets skeletal muscle, regulates the folate–methionine cycle, activates AMPK, and improves insulin sensitivity in rodent models of diet-induced obesity. It is described in the literature as exercise-induced, with treatment of aged mice reported to improve physical capacity and produce adaptations resembling those of physical activity. A pro-diabetogenic mtDNA polymorphism within MOTS-c has been characterised in East Asian populations.
Price is per single sealed vial, in USD. Buying several — volume pricing.
| Vial strength | Price | |
|---|---|---|
| 10mg | $151.20 | Order 10mg |
| 40mg | $532 | Order 40mg |
Links open peer-reviewed sources on PubMed. These are provided so you can read the primary literature yourself. Citing a study is not a claim that this compound is safe or effective for any use in humans.
LY3437943, triple GIP/GLP-1/glucagon receptor agonist
A single-molecule triple agonist at the GIP, GLP-1 and glucagon receptors — the most-discussed metabolic research peptide of the current cycle.
Copper tripeptide-1, glycyl-L-histidyl-L-lysine:Cu(II)
A naturally occurring copper-binding tripeptide whose plasma concentration falls sharply with age; the best-characterised peptide in dermal remodelling literature.
LY3298176, dual GIP/GLP-1 receptor agonist
A unimolecular dual agonist of the GIP and GLP-1 receptors, and the compound behind the SURMOUNT and SURPASS trial programmes.
TH9507, trans-3-hexenoyl-GHRH(1-44)
A stabilised GHRH(1-44) analog and the only GH-axis compound with regulatory approval specifically for reducing visceral adipose tissue.
This website sells laboratory research chemicals. Everything on it is intended for qualified researchers and is not for human or veterinary consumption.
We are sorry — you must be at least 21 years old to view this site. Please close this window.
By entering you confirm you are at least 21 years of age, that you will use all products for laboratory research purposes only, and that you accept our Terms of Sale, Privacy Policy and Research Disclaimer.